Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Objectives: We investigated the population pharmacokinetics and pharmacodynamics of
piperacillin and tazobactam in hospitalized patients. Patients and methods: A multicentre …

Objective: To describe a pharmacokinetic model of piperacillin concentrations in plasma and
subcutaneous tissue when administered by bolus dosing and continuous infusion in …

Piperacillin plasma concentrations are known to vary between critically ill patients. However,
there are no comprehensive data on the variability of antibiotic concentrations within the …

Here we describe the pharmacokinetics of piperacillin administered by continuous infusion
(CI) versus intermittent bolus (IB) dosing in critically ill patients receiving continuous …

Objectives To evaluate the pharmacokinetics of piperacillin/tazobactam in critically ill
patients undergoing continuous renal replacement therapy (CRRT) and to assess the …

Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

In the present study 24 hospitalized patients requiring empirical antibiotic treatment were
randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …

The purpose of this study was to assess the pharmacokinetic (PK) characteristics, clinical
efficiency, and pharmacoeconomic parameters of piperacillin/tazobactam administered by …